Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive to share some exciting news regarding the company's remarkable performance in the third quarter. Valeo Pharma has once again shattered its own records, demonstrating remarkable growth in various key areas of its business. In Q3-23, the company achieved a milestone with record quarterly revenues reaching an impressive $14.1 million. This staggering figure represents a remarkable 132% increase when compared to the $6.1 million generated in the same period of the previous year, Q3-22.
Notably, Valeo Pharma's two flagship products for managing asthma, Enerzair and Atectura, were instrumental in driving this exceptional growth, as they exhibited an astounding 234% increase in sales. What's even more impressive is the surge in adjusted gross profit, which soared to $5.1 million in Q3-23, marking a significant 106% rise from the $2.4 million recorded in Q3-22. Enerzair and Atectura have emerged as frontrunners in the Canadian asthma market, gaining prominence as essential therapies.
The company says they will focus on sales growth and improved gross margins to put themselves on the path to profitability, with plans to optimize costs further. Valeo Pharma's growth story is further underscored by the continuous expansion in the number of prescribing physicians and a surge in total prescriptions. This growth trend has been accelerating quarter after quarter, setting the stage for even more promising opportunities on the horizon. The company is optimistic about its future prospects and anticipates sustained growth as it continues to serve a vital role in addressing healthcare needs.